Clinical Study
The Predictors of Target Lesion Revascularization and Rate of In-Stent Restenosis in the Second-Generation Drug-Eluting Stent Era
Table 5
Lesion characteristics and DS% progression rate according to types of DESs.
| Clinical Factors | Overall | CoCr-EES | ZES | BES | PtCr-EES | P | (N=944) | (N=244) | (N=310) | (N=166) | (N=224) |
| Reference vessel diameter (mm) | 2.92±0.52 | 2.97±0.56 | 2.91±0.52 | 2.96±0.49 | 2.85±0.48 | 0.054 | Lesion length (mm) | 27.73±17.25 | 26.04±16.45 | 28.97±17.98 | 26.56±15.96 | 28.93±18.05 | 0.247 | Pre-procedure MLD (mm) | 0.73±0.50 | 0.76±0.53 | 0.65±0.51 | 0.87±0.44 | 0.71±0.46 | 0.755 | MLD in-segment (mm) | | | | | | | (i) Post-procedure | 2.11±0.52 | 2.13±0.55 | 2.08±0.52 | 2.13±0.50 | 2.11±0.51 | 0.906 | (ii) follow-up | 1.97±0.58 | 1.97±0.59 | 1.99±0.57 | 1.95±0.58 | 1.96±0.58 | 0.726 | (iii) follow-up | 1.96±0.52 | 2.01±0.55 | 1.94±0.52 | 1.96±0.49 | 1.93±0.52 | 0.180 | MLD in-stent (mm) | | | | | | | (i) Post-procedure | 2.48±0.44 | 2.49±0.47 | 2.47±0.43 | 2.47±0.42 | 2.48±0.44 | 0.852 | (ii) follow-up | 2.19±0.60 | 2.19±0.62 | 2.20±0.59 | 2.21±0.59 | 2.15±0.60 | 0.782 | (iii) follow-up | 2.13±0.55 | 2.16±0.61 | 2.12±0.54 | 2.17±0.50 | 2.09±0.54 | 0.480 | Pre-procedure DS (%) | 74.8±15.7 | 74.4±16.0 | 77.0±16.6 | 70.6±13.7 | 75.1±14.9 | 0.431 | DS% in-segment | | | | | | | (i) Post-procedure | 21.5±11.6 | 22.9±12.5 | 21.1±11.8 | 21.4±10.8 | 20.8±11.0 | 0.075 | (ii) follow-up | 26.2±16.5 | 27.3±17.0 | 25.0±15.9 | 27.5±17.6 | 25.8±15.9 | 0.649 | (iii) follow-up | 27.3±15.0 | 27.9±15.8 | 26.2±15.3 | 27.7±12.6 | 28.1±15.2 | 0.624 | DS% in-stent | | | | | | | (i) Post-procedure | 11.8±8.5 | 13.0±8.4 | 10.5±8.8 | 12.6±9.0 | 11.7±7.4 | 0.460 | (ii) follow-up | 22.0±17.5 | 22.4±17.9 | 20.8±16.4 | 21.8±18.3 | 23.3±17.9 | 0.454 | (iii) follow-up | 23.7±15.5 | 24.0±17.8 | 22.8±15.3 | 22.9±12.3 | 25.3±15.5 | 0.346 | Acute gain (mm) | | | | | | | (i) In-segment | 1.38±0.59 | 1.37±0.58 | 1.42±0.63 | 1.26±0.48 | 1.40±0.60 | 0.731 | (ii) In-stent | 1.74±0.54 | 1.73±0.53 | 1.81±0.58 | 1.61±0.47 | 1.75±0.51 | 0.395 | Initial ΔDS | 4.85±15.13 | 4.71±16.53 | 4.00±14.80 | 6.33±14.32 | 5.10±14.59 | 0.457 | In-segment (%) | Initial ΔDS | 10.28±15.89 | 9.52±16.02 | 10.27±15.15 | 9.46±14.43 | 11.72±17.63 | 0.204 | In-stent (%) | Delayed ΔDS | 3.66±11.87 | 3.65±13.52 | 2.82±11.53 | 4.04±9.95 | 4.55±11.81 | 0.264 | In-segment (%) | Delayed ΔDS | 4.59±11.60 | 4.81±14.08 | 3.73±9.87 | 5.27±11.49 | 5.10±11.11 | 0.486 | In-stent (%) | Initial DS%/year in-segment | 6.08±20.77 | 6.48±22.87 | 4.75±17.49 | 10.22 ±29.61 | 4.45±13.00 | 0.841 | Initial DS%/year in-stent | 12.12±20.97 | 12.23±20.92 | 12.15±18.60 | 14.34±29.76 | 10.36±15.74 | 0.525 | Delayed DS%/year in-segment | 2.98±9.84 | 2.65±9.93 | 2.09±9.57 | 3.26±7.89 | 4.30±11.16 | 0.130 | Delayed DS%/year in-stent | 3.68±10.10 | 4.11±12.83 | 2.39±8.13 | 4.02±8.30 | 4.77±10.46 | 0.205 |
|
|
CoCr-EES, cobalt chromium everolimus-eluting stent; ZES, zotarolimus-eluting stent; BES, Biolimus-eluting stent: PtCr-EES, platinum chromium everolimus-eluting stent; MLD, minimal lumen diameter; DS, diameter stenosis.
|